MX2023009091A - Composiciones oftalmologicas topicas. - Google Patents
Composiciones oftalmologicas topicas.Info
- Publication number
- MX2023009091A MX2023009091A MX2023009091A MX2023009091A MX2023009091A MX 2023009091 A MX2023009091 A MX 2023009091A MX 2023009091 A MX2023009091 A MX 2023009091A MX 2023009091 A MX2023009091 A MX 2023009091A MX 2023009091 A MX2023009091 A MX 2023009091A
- Authority
- MX
- Mexico
- Prior art keywords
- ophthalmic composition
- topical ophthalmological
- ophthalmological compositions
- topical ophthalmic
- topical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163145091P | 2021-02-03 | 2021-02-03 | |
| PCT/US2022/014811 WO2022169788A1 (en) | 2021-02-03 | 2022-02-02 | Topical ophthalmological compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009091A true MX2023009091A (es) | 2023-08-09 |
Family
ID=82741579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009091A MX2023009091A (es) | 2021-02-03 | 2022-02-02 | Composiciones oftalmologicas topicas. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12070501B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4288151A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7749020B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230142548A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022217160A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3206612A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023009091A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022169788A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268457B (en) * | 2019-08-04 | 2022-05-01 | Omega 3 Galilee Ltd | Oil- suspension of edible solids and methods of preparing the same |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| WO2025034554A1 (en) * | 2023-08-04 | 2025-02-13 | Ads Therapeutics Llc | Compositions and methods for delivery of ophthalmological actives |
| WO2025131038A1 (en) * | 2023-12-21 | 2025-06-26 | Ads Therapeutics Llc | Compositions and methods for delivery of pharmaceutical actives |
| WO2025259674A1 (en) * | 2024-06-11 | 2025-12-18 | Ads Therapeutics Llc | Compositions and methods for delivery of pharmaceutical actives |
| WO2026003129A1 (en) * | 2024-06-26 | 2026-01-02 | Novaliq Gmbh | Stabilization of (r)-ruxolitinib |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| DE10030378A1 (de) | 2000-06-21 | 2002-03-14 | Audit Inst For Medical Service | Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen |
| CN101049287A (zh) | 2006-04-07 | 2007-10-10 | 财团法人长庚纪念医院 | 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法 |
| US20070254914A1 (en) | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| US20100323978A1 (en) * | 2009-06-22 | 2010-12-23 | Calvin Hanna | Non-aqueous oil delivery system for ophthalmic drugs |
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| CN102526051A (zh) * | 2012-03-09 | 2012-07-04 | 哈尔滨医科大学 | 一种治疗真菌性角膜炎的眼药膏 |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| MX363182B (es) * | 2012-09-12 | 2019-03-13 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) * | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| KR20170120161A (ko) * | 2015-03-05 | 2017-10-30 | 알러간, 인코포레이티드 | 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds) |
| CN109803650A (zh) | 2016-09-28 | 2019-05-24 | 诺瓦利克有限责任公司 | 包含大麻素受体结合配体的组合物 |
| WO2018064354A1 (en) | 2016-09-28 | 2018-04-05 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| WO2018114557A1 (en) | 2016-12-22 | 2018-06-28 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| EP3585386A4 (en) | 2017-02-21 | 2020-12-30 | Singapore Health Services PTE Ltd | COMPOSITION AND PROCESS FOR PREVENTING OR DELAYING THE ONCE OF MYOPIA INCLUDING ATROPINE |
| EP3638643B1 (en) | 2017-06-12 | 2023-01-18 | Novaliq GmbH | Process for the preparation of semifluorinated alkanes using grignard reagents |
| JP7814839B2 (ja) | 2017-09-27 | 2026-02-17 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CN113518619A (zh) | 2019-01-21 | 2021-10-19 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的药物组合物 |
| AU2020216470B2 (en) * | 2019-02-01 | 2023-05-04 | Alcon Inc. | Compounds, compositions and methods for treatment of myopia |
| US11191751B1 (en) | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
-
2022
- 2022-02-02 EP EP22750270.5A patent/EP4288151A4/en active Pending
- 2022-02-02 WO PCT/US2022/014811 patent/WO2022169788A1/en not_active Ceased
- 2022-02-02 JP JP2023547047A patent/JP7749020B2/ja active Active
- 2022-02-02 CA CA3206612A patent/CA3206612A1/en active Pending
- 2022-02-02 AU AU2022217160A patent/AU2022217160A1/en active Pending
- 2022-02-02 KR KR1020237029544A patent/KR20230142548A/ko active Pending
- 2022-02-02 MX MX2023009091A patent/MX2023009091A/es unknown
- 2022-10-28 US US17/976,660 patent/US12070501B1/en active Active
-
2024
- 2024-07-10 US US18/768,656 patent/US12485177B2/en active Active
-
2025
- 2025-09-22 JP JP2025157079A patent/JP2025176201A/ja active Pending
- 2025-11-03 US US19/377,814 patent/US20260124305A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4288151A4 (en) | 2025-01-01 |
| US20260124305A1 (en) | 2026-05-07 |
| KR20230142548A (ko) | 2023-10-11 |
| JP2025176201A (ja) | 2025-12-03 |
| US20250000980A1 (en) | 2025-01-02 |
| EP4288151A1 (en) | 2023-12-13 |
| CA3206612A1 (en) | 2022-08-11 |
| JP7749020B2 (ja) | 2025-10-03 |
| JP2024511695A (ja) | 2024-03-15 |
| WO2022169788A1 (en) | 2022-08-11 |
| US12485177B2 (en) | 2025-12-02 |
| AU2022217160A1 (en) | 2023-08-17 |
| AU2022217160A9 (en) | 2025-01-30 |
| US12070501B1 (en) | 2024-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023006371A2 (pt) | Composição oftalmológica tópica | |
| Steven et al. | Preservatives in glaucoma medication | |
| Aguayo Bonniard et al. | Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK) | |
| MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
| CY1125495T1 (el) | Φαρμακευτικη συνθεση αποτελουμενη αποτιβοζανιμπη | |
| Realini et al. | Low-energy selective laser trabeculoplasty repeated annually: rationale for the COAST trial | |
| MX2025000595A (es) | Compuestos de heteroarilo como degradadores de cinasa 4 asociada al receptor de interleucina 1 (irak4) dirigidos por ligando | |
| CL2011000378A1 (es) | Uso de edta asociado a trometamina o sales de edta oftalmologicamente aceptables asociadas a trometamina, y/o uno o mas fotointensificadores escogidos entre; amarillo de acridina, amarillo de quinidina, azul de metileno, eritrosina; composicion oftalmologica. | |
| ES2182973T3 (es) | Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio. | |
| AR092860A1 (es) | Formulacion oftalmica y metodo para mejorar la presbicia | |
| AR062046A1 (es) | Soluciones oftalmicas | |
| UY28709A1 (es) | Derivados de prostaglandinas | |
| BR112012033111A2 (pt) | método e aparelho para integrar cirurgia de catarata à cirurgia de glaucoma ou astigmatismo | |
| BRPI0821683B8 (pt) | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz | |
| CL2020002619A1 (es) | Composiciones plaguicidas de aceites naturales mejoradas | |
| PA8806901A1 (es) | Nanoparticulas polimericas solidas funcionalizadas que comprenden epotilonas | |
| AR117655A1 (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal | |
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| MX2021015654A (es) | Antagonista del receptor 2 de prostaglandina e2 (ep2). | |
| FI3723739T3 (fi) | Isoksatsoliiniloislääkeformulaatioita ja niiden käyttö silmäluomitulehduksen hoitamiseksi | |
| ES2722723T3 (es) | Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular | |
| US20180021327A1 (en) | Treatment of corneal neovascularization | |
| CO2024014485A2 (es) | Compuestos heterociclicos moduladores de bcl6 como degradadores dirigidos por ligando | |
| Banitt et al. | Ocular surface disease in the glaucoma patient | |
| MX391657B (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular |